We scan new podcasts and send you the top 5 insights daily.
Using the bispecific antibody epcoritamab directly in CLL patients with active disease triggers severe cytokine release syndrome due to high circulating disease burden. Administering fixed-duration venetoclax beforehand debulks tumor load, resulting in significantly lower cytokine release syndrome rates while achieving high undetectable minimal residual disease responses.
Prophylactically administering tocilizumab before bispecific antibody treatment can slash the incidence of cytokine release syndrome (CRS) from ~75% down to 20%. This simple intervention, analogous to using G-CSF for neutropenia, mitigates side effects and makes outpatient administration a much safer and more feasible option for patients.
The LOTUS-7 trial (loncastuximab + glofitimab) illustrates a key principle for using bispecific antibodies safely: combining them with another active, tumor-debulking drug mitigates Cytokine Release Syndrome (CRS). The speaker identifies this as a "thematic" finding, where reducing tumor bulk directly lowers the risk of this major toxicity, making potent combinations more tolerable.
When utilizing the combination of polatuzumab vedotin and mosunetuzumab in aggressive lymphoma, sequencing matters. Giving polatuzumab vedotin first depletes circulating B cells prior to bispecific antibody exposure. Dr. Budde notes that debulking tumor burden and clearing circulating target cells in this manner significantly lowers the subsequent incidence and severity of cytokine release syndrome.
A modified three-step-up dosing schedule for epcoritamab drastically reduced cytokine release syndrome (CRS) rates to 26%, with no severe events. This safety profile supports fully outpatient administration, making this highly effective regimen accessible to community practices without immediate hospital access.
To mitigate the risk of severe Cytokine Release Syndrome (CRS) from bispecific antibodies in patients with high tumor burden, a debulking strategy is effective. Administering two initial cycles of chemotherapy dramatically reduces disease volume, leading to almost zero CRS when the bispecific is introduced, making the treatment much safer.
For CLL patients with bulky adenopathy, clinicians can delay initiating the venetoclax component of a combination therapy. Starting with the BTK inhibitor alone first debulks the tumor, making the subsequent addition of venetoclax safer by decreasing the risk of tumor lysis syndrome.
Administering initial chemotherapy debulking before introducing bispecific antibodies drastically reduces the incidence of cytokine release syndrome in upfront diffuse large B-cell lymphoma. In a phase 2 trial combining glofitumab with R-CHOP, delaying glofitumab initiation until cycle 3 achieved substantial tumor debulking first. Consequently, cytokine release syndrome dropped to 10% while achieving a 90% complete response rate and 95% MRD negativity at 12 months.
Initiating acalabrutinib and venetoclax upfront while delaying obinutuzumab effectively debulks tumor load before antibody exposure. This delayed-layering strategy significantly cuts infusion reactions, myelosuppression, and severe infection risk while preserving the deep responses necessary for complex or autoimmune manifestations.
The AMPLIFY regimen (acalabrutinib + venetoclax) has a built-in safety advantage. The initial two cycles of acalabrutinib monotherapy effectively debulk the disease, significantly reducing the risk of tumor lysis syndrome (TLS) when the potent BCL-2 inhibitor venetoclax is introduced later.
Giving prophylactic tocilizumab before bispecific antibody administration is a highly effective strategy to mitigate Cytokine Release Syndrome (CRS). This approach can reduce CRS rates from ~70% to 5-14%, making outpatient step-up dosing a much more feasible and safer option for community oncology centers.